IP Verse

Low Frequency Glatiramer Acetate Therapy - EP2630962

The patent EP2630962 was granted to Yeda Research on Jun 27, 2018. The application was originally filed on Aug 19, 2010 under application number EP13166080A. The patent is currently recorded with a legal status of "Revoked".

EP2630962

YEDA RESEARCH
Application Number
EP13166080A
Filing Date
Aug 19, 2010
Status
Revoked
May 10, 2024
Grant Date
Jun 27, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALVOGEN IPCOMar 27, 2019HAMM & WITTKOPPADMISSIBLE
HEXALMar 27, 2019SCHUSTWITHDRAWN
G L PHARMAMar 26, 2019HAMM & WITTKOPPADMISSIBLE
SYNTHONMar 26, 2019HAMM & WITTKOPPADMISSIBLE
GENERICS UK TRADING MYLANMar 25, 2019GILL JENNINGS & EVERYADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONEP1210115
OPPOSITIONEP2949335
OPPOSITIONUS2007161566
OPPOSITIONWO0020010
OPPOSITIONWO2007081975
OPPOSITIONWO2011022063
OTHEREP1799703
OTHEREP2177528
OTHEREP2361924
OTHEREP2949335
OTHERUS2007161566
OTHERUS8399413
OTHERUS8969302
OTHERWO2011022063
SEARCHUS2007161566

Non-Patent Literature (NPL) Citations (44) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- ANONYMOUS, "Teva Provides Update on FORTE Trial", INTERNET CITATION, (20080707), URL: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1554743, (20150831), XP002743817
EXAMINATION- YONG WEE V ET AL, "Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (20090301), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A39, XP002743818
OPPOSITION- "A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (NCT01067521)", ClinicalTrials.gov archive, (20100210), XP055581356
OPPOSITION- BEJAOUI K. et al., "There is no rebound worsening of multiple sclerosis after stopping disease-modifying therapies", Multiple Sclerosis, (20080000), vol. 14, pages S31 - S32, XP055508582
OPPOSITION- CAON et al., "P06.141 Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", Neurology, (20090317), vol. 72, no. 11, page A317, XP009161100
OPPOSITION- Comi et al., "Results from a phaseIII, one-year, randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relaping-remitting multiple", Joint Meeting of the American , European , and Latin America Committees on Treatment and Research in Multiple Sclerosis (ACTRIMS, ECTRIMS, LACTRIMS, (20080920), XP055581456
OPPOSITION- "Copaxone 20mg/ml, Solution For Injection, Pre-Filled Syringe", Teva Pharmaceutical, (20090417), pages 1 - 7, XP055579983
OPPOSITION- Costello et al., "Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term", Medscape J Med., (20080930), vol. 10, no. 9, XP055579991
OPPOSITION- Daniel A Husser, "Chapter 100 Patient Compliance", Daniel A Husser, Alfonso R Gennaro, Remington's Pharmaceutical Sciences, (19900000), pages 1813 - 1827, ISBN 0-912734-04-3, XP055581493
OPPOSITION- "Data Published in Neurology showed that higher dosie of Copaxone(R) increased efficacy in relapsing remitting Mutiple Sclerosis (Rrms)", Teva News Release, (20070417), pages 1 - 5, XP055581344
OPPOSITION- DEVONSHIRE et al., "The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis", Mult. Scler., (20061200), vol. 12, page S82, XP055579999
OPPOSITION- "Doubling the Dose of Glatiramer Acetate Does Not Increase Efficacy", MedScape, (20080922), XP055579985
OPPOSITION- FDA Pharmacology Review and Evaluation of Pharmacology and Toxicology Data NDA 20-622 ;
OPPOSITION- Jurgen Koch, "Product Life-Cycle Management for Injectable Drugs: A Good Outlook for Proactive Market Players", Pharmteceutical Technology, (20061202), URL: http://www.pharmtech.com/prod uct-life-cvcle-manaqement-injectable-drugs-good- outl ook-proactive-ma rket -players, XP055579996
OPPOSITION- KHAN et al., "P902 Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day glatiramer acetate 20 mg subcutaneous injections in relapsing-remitting multiple sclerosis", Multiple Sclerosis Late Breaking News, vol. 14, no. suppl.1, (20080900), page s296, URL: https://journals.sagepub.com/doi/pdf/10.1177/1352458508097040, XP009161078
OPPOSITION- KHAN O. et al., "P902 Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day glatiramer acetate 20 mg subcutaneous injections in relapsing-remitting multiple sclerosis", Multiple Sclerosis, (20080900), vol. 14, page S296, XP009161078
OPPOSITION- M. ROVARIS et al., "P570 Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI- measured disease activity in relapsing-remitting multiple sclerosis", Multiple Sclerosis, (20060901), vol. 12, no. 1, suppl, pages II/144 - II/145
OPPOSITION- Multiple Sclerosis, (20090000), vol. 15, pages S249 - S250
OPPOSITION- Rebif® (interferon beta-1 a
OPPOSITION- "Teva initiates phase III study to confirm increased efficacy of higher dose og Glatiramer Acetate for the treatment of relapsing-remitting Multiple Sclerosis", TEVA, (20060727), pages 1 - 4, XP055581348
OPPOSITION- Wang et al., "Parental formulations of proteins and peptides: Stability and stabilizers", Journal of Parenteral Science and Technology, vol. 42, no. 2S, (19880101), pages S3 - S26, XP055253757
OPPOSITION- Yong et al., "Immunological responses to different doses of GA in MS: Analyses from the FORTE trial", Poster sessionI: Multiple Sclerosis: Immunology, (20090428), XP002743818
OPPOSITION- FLECHTER et al., "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", J Neurol Sci, (20020515), vol. 197, pages 51 - 55, XP002679780
OPPOSITION- CALABRESI, "Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose - is more better?", Nature Clinical Practice, (20071000), pages 540 - 541, XP055580629
OPPOSITION- FLECHTER et al., "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: Open multicenter study of alternate-day administration", Clin Neuropharm, (20020000), vol. 25, no. 1, pages 11 - 15, XP009161076
OPPOSITION- COHEN et al., "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS", Neurology, (20070320), vol. 68, no. 12, pages 939 - 944, XP002679784
OPPOSITION- Shi et al., "Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006)", Expert Rev. Pharmacoeconomics Outcomes Res., (20070000), vol. 7, no. 2, pages 187 - 202, XP055579988
OPPOSITION- SIMPSON et al., "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis", CNS D, (20020000), vol. 16, no. 12, pages 825 - 850, XP009161077
OPPOSITION- GAGNON L., "Every-Other-Day Dosing of Glatiramer Acetate Reduces Adverse Reactions with Comparable Efficacy to Daily Dosing", WCTRIMS, (20080921), XP055508581
OPPOSITION- GAGNON L., "Every-Other-Day Dosing of Glatiramer Acetate Reduces Adverse Reactions with Comparable Efficacy to Daily Dosing", WCTRMS, (20080921), XP055508581
OTHER- "COPAXONE ®", Highlights of Prescribing Information, (20090200), XP055465307
OTHER- DEVONSHIRE, "The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis", Mult. Scler., (20060000), vol. 12, no. S1, page 316
OTHER- Expert Rev. Pharmacoeconomics Outcomes Res., (20070000), vol. 7, no. 2, pages 187 - 202
OTHER- "Kapitel 9 - Paranteralia, einschliesslich Blutzubereitunen, Sera und Impfstoffe", Kurt H. Bauer, Karl Heinz Frömming, Claus Führer, Pharmazeutische Technologie, 4., durchgesehene Auflage, Georg Thieme Verlag Stuttgart, (19930000), pages 3pp, 225 - 231, XP055465241
OTHER- Medscape J Med., (20080930), vol. 10, no. 9, page 225
OTHER- Teva Pharmaceutical Industries, "View of NCT01067521 on 2010_02_11; A Multinational, Multicenter, Randomized, Parallel-group Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess Efficacy, Safety and Tolerability of Glatiramer Acetate Injection 40mg Compared to Placebo in a Double-blind Design", ClinicalTrials.gov archive, (20100211), URL: https://clinicaltrials.gov/archive/NCT01067521/2010_02_11, XP055465229
OTHER- G. CO MI et al., "European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis", Ann. Neurol., (20010000), vol. 49, doi:doi:10.1002/ana.64, pages 290 - 297, XP009042363
OTHER- COHEN J A; ET AL, "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS", Neurology, (20070000), vol. 68, no. 12, pages 939 - 944, XP002679784
SEARCH- CAON CHRISTINA ET AL, "Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, (200903), vol. 72, no. 11, Suppl. 3, ISSN 0028-3878, page A317, XP009161100 [A] 1-15 * abstract *
SEARCH- KHAN O ET AL, "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day injections in relapsing -remitting multiple", MULT.SCLER. (14, SUPPL. 1, S296, 2008) 0 REF. ISSN: 1352-4585 AV - WAYNE STATE UNIV, SCH MED, DETROIT, MI, USA., (2008), XP009161078 [A] 1-15 * abstract *
SEARCH- FLECHTER S ET AL, "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", JOURNAL OF THE NEUROLOGICAL SCIENCES, (20020515), vol. 197, no. 1-2, ISSN 0022-510X, pages 51 - 55, XP002679780 [A] 1-15 * abstract *
SEARCH- FLECHTER SHLOMO ET AL, "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.", CLINICAL NEUROPHARMACOLOGY 2002 JAN-FEB LNKD- PUBMED:11852290, (200201), vol. 25, no. 1, ISSN 0362-5664, pages 11 - 15, XP009161076 [A] 1-15 * abstract * * "Comparison of daily with alternate-day treatment" on page 14 and "Drug Supply" on page 12 *
SEARCH- COHEN J A ET AL, "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.", NEUROLOGY 20 MAR 2007 LNKD- PUBMED:17372130, (20070320), vol. 68, no. 12, ISSN 1526-632X, pages 939 - 944, XP002679784 [A] 1-15 * abstract *
SEARCH- SIMPSON DENE ET AL, "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis.", CNS DRUGS, (2002), vol. 16, no. 12, ISSN 1172-7047, pages 825 - 850, XP009161077 [A] 1-15 * "Therapeutic efficacy" on page 835 and "Dosage and Administration" on page 844 * * table II *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents